A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are like...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...
On NOVEMBER 26th, 2024, we organised the webinar: Time to event trial designs in ALS: How useful are they? During this webinar, our speakers Ruben van Eijk, Lotte Smets, Jordi van Unnik and host Lieza Exalto explored the following topics:A...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...
Utrecht, The Netherlands, 05-02-2024GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunc...
On March 12th, we organised the webinar: Getting GRIP on MASH after LITMUSDuring this webinar, our speaker and hosts explored the following topics:The usefulness of noninvasive diagnostic methods depends on the prevalence of the disease ...
On December 12th, we organised the webinar:Revolutionizing Kidney Failure Treatment: Clinical Impact and Lessons Learned from the CONVINCE Clinical TrialDuring this webinar, our speaker and hosts explored the following topics:Study d...
We are proud to announce the publication of our latest research article titled "A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey." This article summarizes the findings of the AwareNASH ...
Last Friday, the results of the CONVINCE trial were published in the prestigious New England Journal of Medicine. We are thrilled to announce that the CONVINCE study has shown that the use of high-dose hemodiafiltration led to a remarkable 23% low...
"*" indicates required fields
"*" indicates required fields
Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities. Read more here
